SUMMARY: Androgen deprivation therapy in 80 men was associated with declines in bone mineral density (BMD), which were greatest in the first year, and in the lumbar spine compared to controls. Vitamin D use was associated with improved BMD in the lumbar spine and in the first year. INTRODUCTION: Decreased BMD is a common side effect of androgen deprivation therapy (ADT), leading to increased risk of fractures. Although loss of BMD appears to be greatest within the first year of starting ADT, there are few long-term studies of change in BMD, and risk factors for bone loss are not well-characterized. METHODS: Men aged 50+ with nonmetastatic prostate cancer starting continuous ADT were enrolled in a prospective longitudinal study. BMD was determined by dual-energy x-ray absorptiometry at baseline and yearly for 3 years. Matched controls were men with prostate cancer not receiving ADT. Multivariable regression analysis examined predictors of BMD loss. RESULTS: Eighty ADT users and 80 controls were enrolled (mean age 69 years); 52.5 % had osteopenia and 8.1 % had osteoporosis at baseline. After 1 year, in adjusted models, ADT was associated with significant losses in lumbar spine BMD compared to controls (-2.57 %, p = 0.006), with a trend towards greater declines at the total hip (p = 0.09). BMD changes in years 2 and 3 were much smaller and not statistically different from controls. Use of vitamin D but not calcium was associated with improved BMD in the lumbar spine in year 1 (+6.19 %, p < 0.001) with smaller nonsignificant increases at other sites (+0.86 % femoral neck, +0.86 % total hip, p > 0.10) primarily in the first year. CONCLUSIONS: Loss of BMD associated with ADT is greatest at the lumbar spine and in the first year. Vitamin D but not calcium may be protective particularly in the first year of ADT use.
SUMMARY: Androgen deprivation therapy in 80 men was associated with declines in bone mineral density (BMD), which were greatest in the first year, and in the lumbar spine compared to controls. Vitamin D use was associated with improved BMD in the lumbar spine and in the first year. INTRODUCTION: Decreased BMD is a common side effect of androgen deprivation therapy (ADT), leading to increased risk of fractures. Although loss of BMD appears to be greatest within the first year of starting ADT, there are few long-term studies of change in BMD, and risk factors for bone loss are not well-characterized. METHODS:Men aged 50+ with nonmetastatic prostate cancer starting continuous ADT were enrolled in a prospective longitudinal study. BMD was determined by dual-energy x-ray absorptiometry at baseline and yearly for 3 years. Matched controls were men with prostate cancer not receiving ADT. Multivariable regression analysis examined predictors of BMD loss. RESULTS: Eighty ADT users and 80 controls were enrolled (mean age 69 years); 52.5 % had osteopenia and 8.1 % had osteoporosis at baseline. After 1 year, in adjusted models, ADT was associated with significant losses in lumbar spine BMD compared to controls (-2.57 %, p = 0.006), with a trend towards greater declines at the total hip (p = 0.09). BMD changes in years 2 and 3 were much smaller and not statistically different from controls. Use of vitamin D but not calcium was associated with improved BMD in the lumbar spine in year 1 (+6.19 %, p < 0.001) with smaller nonsignificant increases at other sites (+0.86 % femoral neck, +0.86 % total hip, p > 0.10) primarily in the first year. CONCLUSIONS: Loss of BMD associated with ADT is greatest at the lumbar spine and in the first year. Vitamin D but not calcium may be protective particularly in the first year of ADT use.
Authors: Angela M Cheung; Lianne Tile; Savannah Cardew; Sandhya Pruthi; John Robbins; George Tomlinson; Moira K Kapral; Sundeep Khosla; Sharmila Majumdar; Marta Erlandson; Judy Scher; Hanxian Hu; Alice Demaras; Lavina Lickley; Louise Bordeleau; Christine Elser; James Ingle; Harriet Richardson; Paul E Goss Journal: Lancet Oncol Date: 2012-02-07 Impact factor: 41.316
Authors: Susan L Greenspan; Penelope Coates; Susan M Sereika; Joel B Nelson; Donald L Trump; Neil M Resnick Journal: J Clin Endocrinol Metab Date: 2005-09-27 Impact factor: 5.958
Authors: Heike A Bischoff-Ferrari; Bess Dawson-Hughes; John A Baron; Peter Burckhardt; Ruifeng Li; Donna Spiegelman; Bonny Specker; John E Orav; John B Wong; Hannes B Staehelin; Eilis O'Reilly; Douglas P Kiel; Walter C Willett Journal: Am J Clin Nutr Date: 2007-12 Impact factor: 7.045
Authors: H A Bischoff-Ferrari; B Dawson-Hughes; H B Staehelin; J E Orav; A E Stuck; R Theiler; J B Wong; A Egli; D P Kiel; J Henschkowski Journal: BMJ Date: 2009-10-01
Authors: Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright Journal: Endocrine Date: 2015-01-31 Impact factor: 3.633
Authors: Derek S Tsang; Jennifer M Jones; Osai Samadi; Suhayb Shah; Nicholas Mitsakakis; Charles N Catton; William Jeon; Joshua To; Henriette Breunis; Shabbir M H Alibhai Journal: Support Care Cancer Date: 2018-03-12 Impact factor: 3.603
Authors: Andrea Dueregger; Isabel Heidegger; Philipp Ofer; Bernhard Perktold; Reinhold Ramoner; Helmut Klocker; Iris E Eder Journal: Nutrients Date: 2014-10-21 Impact factor: 5.717
Authors: F Vescini; R Attanasio; A Balestrieri; F Bandeira; S Bonadonna; V Camozzi; S Cassibba; R Cesareo; I Chiodini; C Maria Francucci; L Gianotti; F Grimaldi; R Guglielmi; B Madeo; C Marcocci; A Palermo; A Scillitani; E Vignali; V Rochira; M Zini Journal: J Endocrinol Invest Date: 2016-03-11 Impact factor: 4.256